XELOX方案联合扶正安中汤、微波热疗治疗晚期结直肠癌患者的近期疗效  

Short-term efficacy of XELOX combined with Fuzheng Anzhong Decoction and microwave hyperthermia in the treatment of advanced colorectal cancer

作　　者：都志豪 李崇慧[2] 黄仁宝[2] 白华 Du Zhihao;Li Chonghui;Huang Renbao;Bai Hua(Graduate School of Anhui University of Chinese Medicine,Hefei Anhui 230031;The First Affiliated Hospital of Anhui University of Chinese Medicine,Hefei Anhui 230031;Anhui Huatuo Academy of Traditional Chinese Medicine,Bozhou Anhui 236800;Medical School of Bozhou Vocational and Technical College,Bozhou Anhui 236800)

机构地区：[1]安徽中医药大学研究生院,安徽合肥230031 [2]安徽中医药大学第一附属医院,安徽合肥230031 [3]安徽省华佗中医药研究院,安徽亳州236800 [4]亳州职业技术学院医学院,安徽亳州236800

出　　处：《山西中医药大学学报》2023年第11期1282-1285,共4页Journal of Shanxi University of Chinese Medicine

基　　金：华佗医学疑难病研究专项(YLFW2307)。

摘　　要：目的:观察XELOX方案联合扶正安中汤、微波热疗治疗晚期结直肠癌的近期疗效,为临床提供合理的治疗方案。方法:选取2022年2月—2023年7月安徽中医药大学第一附属医院肿瘤科收治的60例晚期结直肠癌患者,随机分为对照组、干预组,每组各30例,对照组予以XELOX方案联合微波热疗,干预组在对照组治疗基础上联合扶正安中汤加减,共治疗4个疗程,1个疗程为21 d。观察两组患者治疗前后CD3^(+)、CD4^(+)、CD8^(+)、癌胚抗原(CEA)、糖类抗原199(CA199)、糖类抗原125(CA125)水平、治疗后的近期疗效及不良反应发生率。结果:干预组客观缓解率(ORR)和临床获益率(CBR)分别为50.00%、86.67%,对照组分别为23.33%、63.33%,干预组ORR和CBR明显高于对照组,差异有统计学意义(P<0.05)。治疗后干预组患者CD3^(+)、CD4^(+)水平高于对照组,CD8^(+)、CEA、CA199水平及不良反应(骨髓抑制、恶心呕吐、肝功能异常)发生率低于对照组,差异均有统计学意义(P<0.05,P<0.01)。两组患者治疗后CA125水平及肾功能异常发生率比较,差异无统计学意义(P>0.05)。结论:XELOX方案联合扶正安中汤、微波热疗在一定程度上可提高晚期结直肠癌患者的近期疗效,提高患者免疫功能,降低CEA、CA199水平及不良反应发生率。Objective:To observe the short-term efficacy of XELOX combined with Fuzheng Anzhong Decoction and microwave hyperthermia in the treatment of advanced colorectal cancer,and to provide a reasonable treatment plan for the clinic.Methods:Sixty patients with advanced colorectal cancer admitted to the Oncology Department of the First Affiliated Hospital of Anhui University of Chinese Medicine from February 2022 to July 2023 were randomly divided into control group and intervention group,with 30 patients in each group.The patients in the control group were treated with XELOX combined with microwave hyperthermia,and the patients in the intervention group were treated with modified Fuzheng Anzhong Decoction on the treatment basis of control group.There were 4 courses of treatment,and 1 course was 21 days.The levels of CD3^(+),CD4^(+),CD8^(+),carcinoembryonic antigen(CEA),carbohydrate antigen 199(CA199),carbohydrate antigen 125(CA125)before and after treatment,the short-term efficacy and the incidence of adverse reactions after the treatment were observed in the two groups.Results:The objective response rate(ORR)and clinical benefit rate(CBR)were 50.00%and 86.67%in the intervention group,and 23.33%and 63.33%in the control group,respectively.The ORR and CBR in the intervention group were significantly higher than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of CD3^(+)and CD4^(+)in the intervention group were higher than those in the control group,the levels of CD8^(+),CEA,CA199 and the incidence of adverse reactions(bone marrow suppression,nausea and vomiting,abnormal liver function)were lower than those in the control group,and the differences were statistically significant(P<0.05,P<0.01).There was no statistical significance in CA125 level and incidence of renal dysfunction between the two groups after treatment(P>0.05).Conclusion:XELOX combined with Fuzheng Anzhong Decoction and microwave hyperthermia can improve the short-term efficacy of patients with

关 键 词：晚期结直肠癌 扶正安中汤 微波热疗 化疗 疗效 免疫功能 

分 类 号：R735.35[医药卫生—肿瘤] R735.37[医药卫生—临床医学]